Behind the Nearly 5 Billion Yuan Harvest from Cutting CM Bank Holdings: Hexie Health's Portfolio Reshuffle and Its Core Business Challenge

Deep News11-13

Decisiveness on the investment side and silence on the operating side exist side by side at Hexie Health.

A recent share reduction by Hexie Health has drawn market attention. On November 4, Hexie Health sold approximately 20.238 million A-shares of China Merchants Bank Co., Ltd. (CM BANK), lowering its holding to 1.014 billion shares. CM BANK's third-quarter report showed it still held 1.131 billion shares at the end of September, meaning that over roughly one month since October, Hexie Health has cut close to 117 million CM BANK shares, cashing out an estimated total of nearly 5 billion yuan based on the average transaction price over the period.

This is not an isolated move. Over the past year or more, Hexie Health has successively trimmed stakes in Goldwind Science & Technology, Financial Street and Wanda Information, while on the other side reaping enormous paper gains from early investments in hard-tech companies such as ChangXin Technology and Moore Threads. Cutting on one hand and concentrating on the other, Hexie Health's investment map is undergoing a thorough reshuffle. Yet on another front, the company has gone nine consecutive years without disclosing annual reports or solvency reports, so its core business condition can only be pieced together from scattered public data. The advances and retreats on the investment side, together with the quality of the business side, form the complete coordinates for observing Hexie Health's current stage of development.

An "Inherited" CM Bank Stake, Two Rounds of Reduction in Eight Years Yielding About 11.5 Billion Yuan

First, the reduction itself. On November 4, Hexie Health sold 20.238 million CM BANK A-shares at an average price of 42.595 yuan each, cashing out about 863 million yuan in a single day, with this round totaling nearly 5 billion yuan and its stake falling from 4.48% to 4.02%.

The timing is worth noting. On November 6, CM BANK A-shares closed at 42.88 yuan, with the stock up more than 20% cumulatively since the second half of the year, just a step away from its 2021 historical high. Hexie Health's move at this point makes its intent to realize paper gains quite clear. After the reduction, Hexie Health remains CM BANK's seventh-largest shareholder, with 1.014 billion shares worth roughly 43.5 billion yuan, so this is not a full exit but a measured realization of returns.

In fact, this stake was not bought on the secondary market but "inherited" from within the Anbang system. Before mid-2018, Anbang Property & Casualty held a combined 2.934 billion CM BANK A-shares and H-shares, accounting for 11.63% of total share capital. During the risk disposal of the Anbang group, the relevant holdings were split within the system. In July 2018, Anbang Property & Casualty transferred 1.259 billion A-shares to Hexie Health, representing 4.99% of total share capital, making Hexie Health a major shareholder of CM BANK by default.

Over the following eight years, Hexie Health acted on this stake twice, both times in high price ranges. The first was in the first quarter of 2021, when CM BANK's stock briefly stood above 45 yuan; Hexie Health cut about 128 million shares that quarter, cashing out around 6.55 billion yuan and reducing its stake from 4.99% to 4.48%. The second is the current round, with the two rounds together putting about 11.5 billion yuan in the bag.

Between the two reductions came an unsuccessful attempt. In June 2022, Hexie Health, as a shareholder holding more than 3%, submitted a temporary proposal to CM BANK's shareholders' meeting to elect then-general manager Shen Zheting as a non-executive director of CM BANK's 12th board, but nearly 70% of attending shareholders voted it down and the proposal ultimately failed.

For Hexie Health, with its core executive unable to join CM BANK's board, this nearly 5% stake can essentially only be a financial investment. Stringing these fragments together, the logic becomes clear: the CM BANK stake is an important legacy asset left by the earlier Anbang group risk disposal, and under real-world constraints it cannot be turned into a strategic asset, so its main value lies in monetization. Considering that Hexie Health's net assets were once negative, holding 11.5 billion yuan in cash matters far more for repairing its balance sheet than any change in the shareholding number.

Portfolio Reshuffle: From Real Estate and Banks to Hard Tech

The CM BANK reduction is only the tip of the iceberg. Laying out Hexie Health's investment moves along a timeline reveals a clear trajectory of shift.

The early map bore a strong imprint of the Anbang era. In the first quarter of 2014, Hexie Health, then still part of the Anbang system, bought Financial Street through a universal life insurance account, crossing the 5% stake disclosure line a month later, and by December 2015 raising its holding to 15.88%, for a combined 25% with Anbang Life; by mid-2016, the Anbang system's combined stake had been pushed further to 29.98%, just 1.2 percentage points short of Financial Street Group and its concert parties, making it a landmark case in that year's wave of insurance capital stake-building. At almost the same time, the Anbang system built a stake in wind power leader Goldwind Science & Technology, with Hexie Health establishing a position through universal product accounts and holding it long term, reaching 14.99% after internal integration in 2018, passively rising to largest shareholder in 2021 after the original top shareholder's exchangeable bond conversion, and still holding about 11.6% by the end of 2024.

Real estate, banks, wind power — Hexie Health's heavy-position logic in that era was straightforward: low valuations, high dividends, room for revaluation, using universal life funds to leverage long-term returns from large-cap blue chips. After the equity restructuring was completed in March 2020, Fujia Group received 51% of shares to become Hexie Health's controlling shareholder, and the company began making independent investment moves.

Its first major investment came in December 2020, when it won 117 million Wanda Information shares at 19.92 yuan each through a judicial auction, spending 2.334 billion yuan, ultimately holding a combined 10.05% of Wanda Information and becoming its second-largest shareholder. Wanda Information's main business is smart cities and healthcare IT, offering imagined synergies with a health insurance license; what Hexie Health bought was industrial synergy, not asset revaluation.

But the synergy failed to materialize as hoped. Wanda Information posted losses for years afterward and its stock kept falling, dropping to just above 7 yuan by September 2025, more than 60% below Hexie Health's 19.92 yuan entry cost. Against this backdrop, from January 2025 Hexie Health launched three rounds of reductions: about 123 million yuan cashed out at an average price of 7.54 yuan in January-February; about 222 million yuan at average prices of 7.62 yuan (auction) and 6.89 yuan (block trade) in June-August; and another 291 million yuan at an average price of 6.74 yuan in October-December, cutting more than 6% of shares over the year and slashing its stake from 9.89% to below 2%. By the first quarter of 2026, Hexie Health had exited Wanda Information's top ten shareholder list. Based on disclosed reduction proceeds and the market value of remaining holdings, the paper loss on Hexie Health's 2.334 billion yuan initial investment was of the same magnitude as Wanda Information's share price decline, exceeding 60% overall, and this strategic investment once billed as "medical-insurance synergy" ultimately ended in a stop-loss exit.

The real turnaround came in hard tech. In February 2022, when domestic DRAM maker ChangXin Technology was still loss-making in its private financing stage, Hexie Health invested about 2 billion yuan, holding 1.5% before issuance as its tenth-largest shareholder. Also participating in that round were insurance funds such as China Life Investment, PICC Capital and Sunshine Life; Hexie Health's single investment was nearly double that of the first two and it was the only insurance institution to enter ChangXin Technology's top ten shareholders. At the end of 2022, Hexie Health invested another 500 million yuan in domestic GPU company Moore Threads's Series B financing, holding 1.699% before listing as its 12th-largest shareholder; at the end of 2023 it subscribed 97.8462 million yuan in semiconductor wafer maker Zhonghuan Leading's Series A financing, holding about 1.81%. In addition, Hexie Health took a stake in computing infrastructure company xFusion, currently holding 2.75% (24.2284 million shares) as a joint fifth-largest shareholder and the largest insurance shareholder of xFusion; xFusion's ChiNext IPO application was accepted by the Shenzhen Stock Exchange in May 2026.

These heavy bets on the hard-tech track paid off concentratedly between late 2025 and 2026. In December 2025, Moore Threads listed on the STAR Market as the "first domestic GPU stock," closing up 425% on its first day. Hexie Health's 6.7965 million shares were worth about 4.08 billion yuan, a paper gain of roughly 3.5 billion yuan over the 500 million yuan cost. In July 2026, ChangXin Technology listed on the STAR Market, raising about 57.9 billion yuan in the year's largest A-share IPO, closing its first day at 49 yuan, up 465.82%. Hexie Health's 901 million shares were worth about 44.15 billion yuan, a paper gain of roughly 42.2 billion yuan on the approximately 2 billion yuan initial cost, a return of over 20 times. Even though Moore Threads and ChangXin Technology shares have since fluctuated, based on early November closing prices Hexie Health's two hard-tech holdings were worth nearly 38.8 billion yuan combined, a paper gain of about 36 billion yuan over the 2.5 billion yuan initial cost — a very considerable return.

Of course, alongside the hard-tech harvest came a systematic contraction of the old map. Hexie Health's reduction of Goldwind Science & Technology ran through all of 2025, with its stake falling from 11.5% at the start of the year to below 5% by year-end, exiting the major shareholder ranks; it reduced further in succession from late March to early April 2026, cashing out about 4.85 billion yuan. Financial Street has also been reduced as many as six times since November 2025, with about 149 million shares sold through centralized bidding from late June to early November 2026 alone, pushing its stake down from around 15% to 10%, with the company citing "its own operating needs." Add this round's nearly 5 billion yuan CM BANK reduction, and the picture of Hexie Health fully repatriating capital is fairly complete.

Putting Hexie Health's more than a decade of investment advances and retreats together, the strategic shift is clearly visible. In targets, it has moved from traditional blue chips in real estate, banking and wind power to hard tech in semiconductors, artificial intelligence and computing power, from earning money on asset revaluation to earning money on industrial growth; in approach, the Anbang era's secondary-market stake-building with universal life funds has given way to more early-stage primary-market entry, accompanying companies through loss periods and exiting via IPO; in rhythm, old assets are monetized in batches at highs while new assets are held long term, with the portfolio shifting from stock-heavy to increment-heavy.

This strategic shift in Hexie Health's investments is in fact highly aligned with current capital market direction. Regulators advocate that insurance funds act as "patient capital," and the STAR Market opens financing channels for hard-tech companies; Hexie Health's early-entry, long-hold model sits right at the intersection of the two. At the same time, it should be noted that the hard-tech paper gains remain on the books, Hexie Health's shares are subject to lock-up periods, and the semiconductor industry cycle is highly volatile, so how much is ultimately realized depends on exit timing and rhythm. Between paper wealth and money in hand lies more than just time.

However Impressive the Investment Side, It Must Return to the Core Business

An insurance company is ultimately a business of managing liabilities. Money earned on the investment side must ultimately be used to honor policies, support underwriting and shore up solvency; the premium structure and quality on the liability side in turn determine the funding cost on the investment side. No matter how many investment moves are made, they must all return to the core business for examination. And Hexie Health's core business is precisely the part hardest to see clearly today.

It is hard to see clearly because disclosure has long been absent. Since 2017, Hexie Health has not disclosed an annual report, and its solvency reports stop at the first quarter of 2017, when core and comprehensive solvency adequacy ratios were both 102.01%, already close to the regulatory red line. The three-year solvency transition period granted by regulators at the 2020 equity transfer expired in April 2023. On April 30, 2026, the company's website posted its ninth notice of delayed annual report disclosure, still citing being "in the transition period of risk disposal." The only window for outside observers is a few social responsibility reports.

Based on such scattered data, the scorecard has bright spots. The company's operating scale has expanded rapidly over the past four years, with revenue rising from 35.598 billion yuan in 2022 to 57.822 billion yuan in 2023 and 75.325 billion yuan in 2024, reaching 75.826 billion yuan in 2025; original insurance premium income rose from 46.05 billion yuan in 2023 to 64.116 billion yuan in 2024, up 39.23% year on year; by the end of 2024, total assets reached 452.05 billion yuan, nearly double the level when Fujia Group took over. For reference, PICC Health's original premium income in 2023 was 45.208 billion yuan, meaning Hexie Health's premium scale had already surpassed PICC Health in 2023, putting it at the top of professional health insurance companies.

Business quality has also improved markedly. In 2025, Hexie Health's 13-month premium continuation rate rose from 66.64% before the equity transfer to 97.35%, and claim payment turnaround fell from 13.61 days to 1.15 days, putting policy continuation in the industry's first tier. The company also claims net assets have exceeded 75 billion yuan and embedded value topped 80 billion yuan; compared with negative net assets before the equity transfer, Hexie Health has indeed completed a difficult stop-the-bleeding and repair over six years.

But the data also hides weaknesses, the most glaring being claims. In 2023, Hexie Health had 46.05 billion yuan in original premiums but paid only 722 million yuan in claims that year; under the same measure, PICC Health, with almost identical premium scale, paid 23.46 billion yuan — more than thirty times the difference. The reasonable inference is a difference in business structure. Hexie Health's premiums come mostly from products such as nursing insurance with strong savings attributes, mainly maturity payouts, so reimbursement-type claim expenses are naturally very low; PICC Health focuses on mature protection-type health insurance with more rigid claims. In other words, Hexie Health is nominally in "health insurance" but in practice has a low proportion of protection functions on the underwriting side, earning more from the spread, and its reliance on investment returns follows from that.

The weakness also shows in operating stability. In 2025, Hexie Health's scale premiums were 63.458 billion yuan, down about 1% year on year, with high growth hitting the brakes; the scope of its social responsibility report also narrowed, with claim amounts and claim counts no longer disclosed after 2024, and total assets absent in 2025 as well. Combined with the lack of information disclosure, it is very hard for outsiders to judge Hexie Health's true current business operating capability.

The management situation partly explains this instability. According to its website, Hexie Health's current chairman Zhao Jianxin previously worked at Taikang Life, Sun Life Everbright Life and Minsheng Life, with a career concentrated in actuarial lines; he was elected chairman in 2025 and formally took office in June 2026 with the announcement of the fourth board. An actuary-turned-leader is usually more sensitive to liability costs and asset-liability matching, consistent with Hexie Health's recent strategy of reducing single-premium business and shifting toward value-oriented regular-premium business.

The general manager post is a different story. In the first half of 2022, Shen Zheting, formerly vice president and chief actuary of Fosun United Health, was approved as Hexie Health's general manager, but resigned for personal reasons after just over a year. Since then Guan Bin has presided over work as temporary head, and more than three years on has still not been formally confirmed. Guan Bin has served as general manager of New China Life's Fujian branch, assistant president of Minsheng Life, deputy general manager of德华安顾 Insurance and chairman and general manager of Huakang Insurance Agency, with fairly complete frontline and small-to-mid-sized institution management experience, but a temporary label lasting three years itself shows that a formal candidate has yet to be settled.

Similar situations appear in other key posts. The chief actuary position has been vacant for nearly two years since Xu Qiang left in January 2024, with two successive temporary heads not confirmed, until Liu Jianxun — holding a North American actuary qualification and having worked at Munich Re and China Post Life — took over in 2026; the finance head has also changed several times and is still temporarily held by Zhang Xiaomin, nearly three years on without formal confirmation. The remaining vice general manager Cheng Xiaoyang, board secretary Wang Yili, compliance head Cao Shuying and audit head Gao Zheming are among the few stable core members of the company's senior management team, each serving in their posts for more than four years.

Conclusion

Cashing out nearly 5 billion yuan as CM BANK shares approach historical highs on one hand, while holding hundreds of billions of yuan in paper gains from hard-tech investments on the other; premium scale pushing into the industry's front ranks on one hand, while claim payouts are disproportionately low for its size on the other; nine consecutive years without an annual report, and the general manager seat empty for three years. Interwoven, these main threads form the realistic picture of Hexie Health at the operating level.

Decisiveness on the investment side and silence on the operating side exist simultaneously at Hexie Health. The capital repatriated through reductions and the book appreciation have indeed greatly repaired the company's net assets since emerging from risk disposal, and that should not be denied. But for an insurance company, what the market ultimately looks at is whether the underwriting side can build genuine protection capability, whether governance can move toward stability, and when that information disclosure window, closed for nine years, will reopen. The answers to these questions matter more than any single reduction or paper gain.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment